Colon Cancer Symptoms - Genentech continues early-stage colon cancer study - KTVN.com
Genentech continues early-stage colon cancer study - KTVN.com
SOUTH SAN FRANCISCO, Calif. (AP) - Biotechnology company Genentech Inc. said Monday a late-stage study of Avastin focusing on early-stage colon cancer will continue, following an independent safety analysis. The current study, being conducted by the
Genentech to continue Phase III colon cancer study - Pharmaceutical Business Review
The National Surgical Adjuvant Breast and Bowel Project’s (NSABP) decision to continue the trial was based on a recommendation from an independent data monitoring committee (DMC) after a planned interim analysis. The study of 2,710 patients is being
Genentech Continues Avastin Colon Study - eNews 2.0
The leading biotechnology company Genentech Inc. said a Phase III study of its drug Avastin focusing on early-stage colon cancer will not be discontinued. The 2,710-patient clinical study, which is carried out by the National Surgical Adjuvant Breast
Colon Cancer Drug Won’t Help Those With Certain Gene Mutation - WAFF
WEDNESDAY, Oct. 22 (HealthDay News) — A new study suggests that people with advanced colon cancer who have a particular gene mutation won’t benefit from the medication cetuximab (Erbitux). While the drug can add months to the lives of people without
Task force: Colon screenings can stop at 75 - Daily Local News
Most people over 75 should stop getting routine colon cancer tests, according to a government health task force that also rejected the latest X-ray screening technology. The U.S. Preventive Services Task Force in a break with other medical and